Skip to main
HQY
HQY logo

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 54%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

HealthEquity Inc. reported strong financial results for Q2/26, with total revenue increasing by 8.6% year-over-year to $325.8 million, driven primarily by a significant 15.3% growth in custodial revenue, which accounted for 49.1% of the total revenue. The company's health savings account (HSA) cash reached $17.035 billion, reflecting a 4% year-over-year increase, while HSA investments rose by an impressive 24% to $16.1 billion, showcasing robust growth in both account balances and investment participation. Additionally, interchange revenue grew by 8.0% to $48.1 million, supported by an increase in total accounts and higher spending per account, reinforcing the company's positive momentum in the consumer-directed benefits market.

Bears say

HealthEquity's stock is currently trading at multiples lower than both its high-growth SaaS peer group average and its own five-year valuation averages, indicating potential overvaluation amid a backdrop of declining performance with shares down 7% year-to-date. Additionally, while revenue forecasts for FY/27 remain stable, the adjusted EBITDA projection has been revised downward, highlighting concerns over profitability despite expected revenue growth. The company faces several risks, including increased competition, regulatory challenges, and economic factors such as falling interest rates, which could further impact its financial stability and market position.

HealthEquity (HQY) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 54% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 13 analysts, HealthEquity (HQY) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.